CancerVax Corporation announces corporate restructuring and Crucell to release third quarter results on Monday, October 17.

0 Comments | M2 Presswire, October, 2005

M2 PRESSWIRE-4 October 2005-US Financial Network: CancerVax Corporation announces corporate restructuring and Crucell to release third quarter results on Monday, October 17(C)1994-2005 M2 COMMUNICATIONS LTD RDATE:04102005 City of Industry, CA - Biotechnoly industry news provided by Financial News USA (OTC: FNWU) CancerVax Corporation (NASDAQ: CNVX) announced a corporate restructuring plan today, realigning its resources in light of its decision to discontinue the Phase 3 clinical trial of Canvaxin(TM) in patients with Stage III melanoma.

The immediate impact of this restructuring will reduce CancerVax's workforce from 183 to approximately 80 employees. Dutch biotechnology company Crucell N.V. (Nasdaq: CRXL) recently announced that it will release its...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research
 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)